Thrombophilia and Adverse Pregnancy Outcome

Clinics in Perinatology

Volumn 34, Issue 4, 2007, Pages 527-541

  Brenner, Benjamin ^a   Aharon, Anat ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 5 LEIDEN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; FETUS WASTAGE; GENE MUTATION; GENOTYPE; GESTATION PERIOD; HEMOSTASIS; HUMAN; INFANT DISEASE; INTRAUTERINE GROWTH RETARDATION; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREVALENCE; PRIORITY JOURNAL; PUERPERIUM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOLUTIO PLACENTAE; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ABRUPTIO PLACENTAE; FEMALE; FETAL DEATH; FETAL GROWTH RETARDATION; HEMOSTASIS; HUMANS; HYPERHOMOCYSTEINEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RISK FACTORS; THROMBOPHILIA;

EID: 36549052111     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2007.09.002     Document Type: Review

References (66)

1. Brenner B. Clinical management of thrombophilia-related placental vascular complications. Blood 103 11 (2004) 4003-4009
2. Bremme K., Ostlund E., Almqvist I., et al. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol 80 1 (1992) 132-137
3. Bremme K.A. Hemostatic changes in pregnancy. Ballieres Best Pract Res Clin Haematol 16 2 (2003) 153-168
4. Comp P.C., Thurnau G.R., Welsh J., et al. Functional and immunologic protein S levels are decreased during pregnancy. Blood 68 4 (1986) 881-885
5. Cumming A.M., Tait R.C., Fildes S., et al. Development of resistance to activated protein C during pregnancy. Br J Haematol 90 3 (1995) 725-727
6. Stirling Y., Woolf L., North W.R., et al. Haemostasis in normal pregnancy. Thromb Haemost 52 2 (1984) 176-182
7. Kruithof E.K., Tran-Thang C., Gudinchet A., et al. Fibrinolysis in pregnancy: a study of plasminogen activator and inhibitors. Blood 69 2 (1987) 460-466
8. Giavarina D., Messena G., Dorizzi R.M., et al. Reference interval of D-dimer in pregnant women. Clin Biochem 34 4 (2001) 331-333
9. Aharon A., Brenner B., Katz T., et al. Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells: implications for placental hemostasis. Thromb Haemost 92 4 (2004) 776-786
10. Sanson B.J., Friederich P.W., Simioni P., et al. The risk of abortion and stillbirth in antithrombin, protein C, and protein S-deficient women. Thromb Haemost 75 3 (1996) 387-388
11. Haverkate F., and Samama M. Familial dysfibrinogenemia and thrombophilia: report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 73 1 (1995) 151-161
12. Sarig G., Hoffman R., Younis J., et al. Thrombophilia is common in women with pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 77 2 (2002) 342-347
13. Press R.D., Bauer K.A., Kujovich J.L., et al. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 126 11 (2002) 1304-1318
14. Brenner B.R., Nowak-Gottl U., Kosch A., et al. Diagnostic studies for thrombophilia in women on hormonal therapy and during pregnancy, and in children. Arch Pathol Lab Med 126 11 (2002) 1296-1303
15. Meinardi J.R., Middeldorp S., de Kam P.J., et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 130 9 (1999) 736-739
16. Brenner B., Mandel H., Lanir N., et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 97 3 (1997) 551-554
17. Rey E., Kahn S.R., David M., et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 361 9361 (2003) 901-908
18. Martinelli I., Taioli E., Cetin I., et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 343 14 (2000) 1015-1018
19. Erez O., Hoppensteadt D., Romero R., Espinoza J., Goncalves L., Nien J.K., Kusanovic J.P., Fareed J., Gotsch F., Pineles B., and Chaiworapongsa T. Preeclampsia is associated with low concentrations of protein Z. J Matern Fetal Neonatal Med 20 (2007) 661-667
20. Preston F.E., Rosendaal F.R., Walker I.D., et al. Increased fetal loss in women with heritable thrombophilia. Lancet 348 9032 (1996) 913-916
21. Tal J., Schliamser L.M., Leibovitz Z., et al. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod 14 6 (1999) 1624-1627
22. Brenner B. Thrombophilia and pregnancy loss in first intended pregnancy. J Thromb Haemost 3 10 (2005) 2176-2177
23. Lissalde-Lavigne G., Fabbro-Peray P., Cochery-Nouvellon E., et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control 'NOHA first' study. J Thromb Haemost 3 10 (2005) 2178-2184
24. Sanson B.J., Lensing A.W., Prins M.H., et al. Safety of low molecular weight heparin in pregnancy: a systemic review. Thromb Haemost 81 5 (1999) 668-672
25. Lepercq J., Conard J., Borel-Derlon A., et al. Venous thromboembolism during pregnancy: a retrospective of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol 108 11 (2001) 1134-1140
26. Greer I.A., and Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106 2 (2005) 401-407
27. Kominiarek M.A., Angelopoulos S.M., Shapiro N.L., Studee L., Nutescu E.A., and Hibbard J.U. Low-molecular-weight heparin in pregnancy: peripartum bleeding complications. J Perinatol 27 (2007) 329-334
28. Abou-Nassar K., Kovacs M.J., Kahn S.R., Wells P., Doucette S., Ramsay T., Clement A.M., Khurana R., Mackinnon K., Blostein M., Solymoss S., Kingdom J., Sermer M., Rey E., and Rodger M. TIPPS investigators. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia - A randomized trial. Thrombosis and Haemostasis 98 1 (2007) 163-171
29. Brenner B., Hoffman R., Blumenfeld Z., et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 83 5 (2000) 693-697
30. Carp H., Dolitzky M., and Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 1 3 (2003) 433-438
31. Gris J.C., Mercier E., Quere I., et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 103 10 (2004) 3695-3699
32. Brenner B., Hoffman R., Carp H., et al. LIVE-ENOX Investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 3 2 (2005) 227-229
33. Brenner B., Bar J., Ellis M., et al. LIVE-ENOX Investigators. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the LIVE-ENOX study. Fertil Steril 84 3 (2005) 770-773
34. Martinelli P., Grandone E., Colaizzo D., et al. Familial thrombophilia and the occurrence of fetal growth restriction. Hematologica 86 4 (2001) 428-431
35. Grandone E., Colaizzo D., Brancaccio V., et al. Low birth weight in neonates of mothers carrying factor V G1691A and factor A 20210 mutations. Hematologica 87 10 (2002) 177-181
36. Infante-Rivard C., Rivard G.E., Yotov W.V., et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 347 1 (2002) 19-25
37. Kupferminc M.J., Eldor A., Steinman N., et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 340 1 (1999) 9-13
38. Greer I.A. Pathological processes in pregnancy-induced hypertension and intrauterine growth retardation 'an excess of heated blood.'. In: Greer I.A., Turpie A.G.G., and Forbes C.D. (Eds). Haemostasis and thrombosis in obstetrics and gynaecology (1992), Chapman and Hall, London, England 163-202
39. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 [sFlt1] may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 5 (2003) 649-658
40. Koga K., Osuga Y., Yoshino O., et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrin Metab 88 5 (2003) 2348-2351
41. Benedetto C., Marozio L., Saslton L., et al. Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome. Acta Obstet Gynecol Scand 81 12 (2002) 1095-1100
42. Grandone E., Margaglione M., Colaizzo D., et al. Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to pre-eclampsia. Thromb Haemost 77 6 (1997) 1052-1054
43. De Groot C.J., Bloemenkamp K.W., Duvekot E.J., et al. Preeclampsia and genetic risk factors for thrombosis: a case control study. Am J Obstet Gynecol 181 4 (1999) 975-980
44. Morrison E.R., Miedzybrodzka Z.H., Campbell D.M., et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 87 5 (2002) 779-785
45. Mello G., Parretti E., Marozio L., et al. Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. Hypertension 46 6 (2005) 1252-1253
46. Larciprete G., Gioia S., Angelucci P.A., Brosio F., Barbati G., Angelucci G.P., Frigo M.G., Baiocco F., Romanini M.E., Arduini D., and Cirese E. Single inherited thrombophilias and adverse pregnancy outcomes. J Obstet Gynaecol Res 33 (2007) 423-430
47. Kupferminc M.J., Fait G., Many A., et al. A low molecular weight heparin for the prevention of obstetric complications in women with thrombophilia. Hypertens Preg 20 1 (2001) 35-44
48. Grandone E., Brancaccio V., Colaizzo D., et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril 78 2 (2002) 371-375
49. Goddijn-Wessel T.A., Wouters M.G., van de Molen E.F., et al. Hyper-homocystinemia: a risk factor for placental abruption or infarction. Eur J Ostet Gynecol Reprod Biol 66 1 (1996) 23-29
50. Vollset S.E., Refsum H., Irgens L.M., et al. Plasma total homocysteine pregnancy complications and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr 71 4 (2000) 962-968
51. Nelen W.L., Blom H.J., Steegers E.A., et al. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril 74 6 (2000) 1196-1199
52. Gris J.C., Quere I., Monpeyroux F., et al. Case control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent-the Nimes Obstetricians and Haematologists Study 5 (NOHA5). Thromb Haemost 81 6 (1999) 891-899
53. Wiener-Megnagi Z., Ben-Shlomo I., Goldberg Y., et al. Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol 179 6 Pt 1 (1998) 1565-1567
54. Prochazka M., Happach C., Marsal K., et al. Factor V Leiden in pregnancies complicated by placental abruption. Br J Obstet Gynaecol 110 5 (2003) 462-466
55. Procházka M., Lubuský M., Slavík L., Hrachovec P., Zielina P., Kudela M., and Lindqvist P.G. Frequency of selected thrombophilias in women with placental abruption. Aust N Z J Obstet Gynaecol 47 (2007) 297-301
56. Sarig G., Blumenfeld Z., Leiba R., et al. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. Thromb Haemost 94 5 (2005) 980-985
57. Aharon A., Lanir N., Drugan A., et al. Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment. J Thromb Haemost 3 10 (2005) 2355-2357
58. Gerhardt A., Scharf R.E., Beckmann M.W., et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 342 6 (2000) 374-380
59. Rai R., Cohen H., Dave M., et al. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies. BMJ 314 7076 (1997) 253-257
60. Franchi F., Biguzzi E., Cetin I., et al. Mutations in the thrombomodulin and endothelial protein C receptor genes in women with late fetal loss. Br J Haematol 114 3 (2001) 641-646
61. Laude I., Rongieres-Bertrand C., Boyer-Neumann C., et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost 85 1 (2001) 18-21
62. Goswami D., Tannetta D.S., Magee L.A., Fuchisawa A., Redman C.W., Sargent I.L., and von Dadelszen P. Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta 27 (2006) 56-61
63. Tesse A., Meziani F., David E., Carusio N., Kremer H., Schneider F., and Andriantsitohaina R. Microparticles from preeclamptic women induce vascular hyporeactivity in vessels from pregnant mice through an overproduction of NO. Am J Physiol Heart Circ Physiol 293 (2007) H520-H525
64. Greer I.A. Procoagulant microparticles: new insights and opportunities in pregnancy loss?. Thromb Haemost 85 1 (2001) 3-4
65. Sarig G., Lanir N., Hoffman R., et al. Protein C global assay in the evaluation of women with idiopathic pregnancy loss. Thromb Haemost 88 1 (2002) 32-36
66. Sood R., Kalloway S., Mast A.E., et al. Feto-maternal cross-talk in the placental vascular bed: control of coagulation by trophoblast cells. Blood 107 (2006) 3173-3180